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Abstract
This paper focuses on HTA, pricing and reimbursement of pharmaceuticals in Germany and Poland. The authors analyzed processes of decision 
making related to pharmaceutical reimbursement, as well as their transparency. Both Germany and Poland have developed complex processes of 
pharmaceutical pricing and reimbursement, as well as incorporated HTA into decision making procedures. In Germany the stakeholders involvement 
and transparency of processes seem to be to higher than in Poland. 
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Introduction
Pricing and reimbursement of pharmaceuticals in 
Germany and Poland are regulated at national levels, 
similarly to other countries of the European Union (EU). 
Therefore they are as different as health care systems of 
both countries are. In Germany the authorities of self-
governing states called lands have a lot of power, so deci-
sion making within health care system is shared between 
federal and state levels [1]. The key policy maker and 
regulator in the Polish health care system is the Minister 
of Health (MoH), often supported by advisory bodies [2].
Nowadays, before a decision on medicine’s reim-
bursement, pricing, or both of these issues is made within 
a given health care system, usually a particular medici-
nal product has to be thoroughly evaluated. The tools of 
Health Technology Assessment (HTA) are used for this 
purpose both in Germany and Poland. The HTA, which 
has an increasing role in today’s health care systems, is 
often being applied in case of products which are new on 
the market and claimed to bring an additional therapeutic 
benefit to patients. In the growing number of countries 
there have been established agencies or programmes 
specialized to evaluate health technologies and this has 
been the case also in Germany and Poland. There are 
many challenges in implementation of HTA into decision 
making processes, including the assurance of appropri-
ate level of transparency [3]. High transparency has been 
also considered as an important feature of robust phar-
maceutical pricing [4]. Starting from 1989 it has become 
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a major requirement imposed on all EU Member States 
by the Transparency Directive [5].
The aim of this paper is to compare and critically as-
sess the systems of pricing and reimbursement of pharma-
ceuticals in Germany and Poland, taking into considera-
tion practical implementation of HTA and transparency 
of HTA and reimbursement processes within health care 
decision making.
There have been several reasons for choosing these 
two countries. Their national pharmaceutical markets are 
being influenced by each other through parallel trade, 
benchmarking in pharmaceutical policies and interna-
tional price comparisons. Both pharmaceutical markets 
function in relatively stable economic environments, 
since both German and Polish economies have been do-
ing quite well during the economic crisis and slowdown 
affecting countries of the EU since 2007.
Material and Methods
In order to achieve this study objectives, firstly the 
pharmaceutical reimbursement and HTA processes in 
Germany and Poland have been generally described and 
compared. Secondly, transparency of decision making 
related to pharmaceutical pricing and reimbursement and 
HTA processes in both countries has been analysed and 
assessed.
In order to compare transparency of processes of 
pharmaceutical pricing and reimbursement, and HTA, 
their measurable features have been identified and taken 
into consideration. Transparency has been expressed as 
the involvement of stakeholders (pharmaceutical com-
panies, physicians, pharmacists and the general public) 
at various stages of HTA process, communication with 
health care system stakeholders and clarity of HTA 
guidelines.
The search for studies published after 2010 was con-
ducted in databases Medline and Embase. In Medline the 
MeSH terms were used in searches when it was possi-
ble. The following search terms were used: “Germany, 
Poland, health technology assessment, pharmaceutical, 
reimbursement and pricing”. The terms “Germany” and 
“Poland” were first connected with “health technol-
ogy assessment” using operator AND. Subsequently 
they were connected with “economics, pharmaceutical 
[MeSH] OR pharmaceutical pricing OR drug pricing” 
with operator AND.
All records were screened for duplicates, which were 
subsequently excluded. After that, all titles and abstracts 
of identified studies were screened for relevance. The full 
texts of eligible studies were read and reviewed. Bibli-
ography reference lists of the pertinent studies were also 
reviewed in order to identify other, possibly eligible stud-
ies. In addition to that, content of websites of German and 
Polish institutions involved in HTA and national pharma-
ceutical pricing and reimbursement policies was also re-
viewed. The language selection criteria in this systematic 
review included English or German. The studies were 
excluded if they did not match the inclusion criteria or if 
they appeared irrelevant to the study goals. The records 
describing processes of HTA and pharmaceutical pricing 
and reimbursement in Germany and Poland, taking into 
consideration also transparency of these processes, were 
included into analysis.
Results
The flow diagram describing selection process of the 
published studies has been presented in Figure 1. Alto-
gether 302 records were identified. After removing du-
plicates and screening records for relevance, nine papers 
[3, 4, 6–12] in full-text versions and eight conference 
abstracts [13–20] were selected for further analysis. The 
summary set of analyzed features of pharmaceutical pric-
ing, reimbursement and HTA utilization in both countries 
has been presented in Figure 2.
Processes of pharmaceutical reimbursement and HTA  
in Germany and Poland
Prices of pharmaceuticals are being set and defined 
in different ways in various countries. According to the 
Glossary of the WHO Collaborating Centre for Pharma-
ceutical Pricing and Reimbursement Policies, list prices 
are “the prices that purchasers display as the prices at 
30 articles excluded 
on full text: 
–  Irrevelant aspects 
described (e.g. 
reaction of manu-
facturers to recom-
mendations) 22
– other countries 5
–  Not according to 
actual law 3
302 records screened 
for relevance
272 records screened 
for relevance
97 records screened 
for relevance
48 potentially relevant 
records revised
10 Articles and 
8 abstracts finally 
included
30 records removed 
(duplicates)
175 records excluded 
on title
49 articles excluded 
on abstract
Figure 1. Flow diagram of study selection process.
Source: Own elaboration.
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which they are prepared to sell their products and/or reg-
ulated by legislation. The prices of products as quoted in 
the purchaser’s price list, catalogue, internet site, adver-
tisements, in a national price list/formulary, etc. They are 
not necessarily actual transaction prices.” [21]. According 
to the same bibliographic source the reimbursement price 
“is the basis for reimbursement of medicines in a health 
care system, i.e. the maximum amount paid for by a third 
party payer” [21]. However, pricing processes can be dif-
ferent across countries, therefore notion of a medicine’s 
price of should be seen in context of a particular health 
care system’s legislation.
The reimbursement of pharmaceuticals is closely 
related to patient co-payment rules, which exist in a par-
ticular country. In Germany patient pays usually 10% of 
medicine’s price, but minimum EUR 5.00 and maximum 
EUR 10.00. If price is lower than EUR 5.00, patient 
pays it in full [1]. There are four levels of pharmaceuti-
cal co-payment in Poland, i.e. flat rate (PLN 3.20) per 
package containing up to 30 Defined Daily Doses (DDD) 
of a medicine, 0%, 30%, 50% and 100% of reimburse-
ment limit, which is set closely to price of the cheapest 
medicine either from among equivalents having the same 
international name and form or from among similar drugs 
within the same therapeutic group [2]. If a particular 
medicine’s price exceeds its reimbursement limit a dif-
ference has to be paid by patient.
In Germany the processes of pharmaceutical reim-
bursement and HTA associated with it are the same for 
nearly all medicines, with exceptions only for drugs with 
low budgetary impact and drugs used in treatment of rare 
diseases [4]. The overview of these processes are present-
ed in Figure 3. They start with a review of dossier pro-
vided by pharmaceutical manufacturer. If manufacturer 
applies to negotiate a reimbursement price for a new drug 
with the Statutory Health Insurance (SHI), it is obliged to 
present a dossier containing evidence on the additional 
therapeutic benefit of a given drug. There are six levels of 
this benefit: (1) major additional benefit, (2) considerable 
additional benefit, (3) minor additional benefit, (4) un-
quantifiable additional benefit, (5) no additional benefit 
and (6) benefit smaller than that of medicines which are 
already present on the market [6].
If manufacturers do not provide any evidence on ad-
ditional benefit, their drugs are included directly into the 
Processes of pharmaceutical 
reimbursement 
and HTA
• rules of patient co-payment
• methodology of HTA applied in 
pharmaceutical reimbursement
• complexity of pricing and reimbur-
sement rules
• involvement of state institutions
Stakeholder involvement in 
pharmaceutical pricing and 
reimbursement sales
• payers
• health care professionals
• patients and the general public
• politicians and the MoH
• manufacturers
Transparency of decison 
making within drug pricing 
and reimbursement
• compliance with the EU’s Transpa-
rency Directive
• approach to publication of do-
cuments related to pricing and 
reimbursement processes
Figure 2. The summary set of analyzed features of pharmaceutical pricing, reimbursement and HTA utilization in Germany and 
Poland.
Source: Own elaboration.
Figure 3. Reimbursement and HTA process in Germany. 
Source: Own elaboration on Gerber A., Stock S., Dintsios C.-M., 
Reflections on the changing face of German pharmaceutical 
policy: how far is Germany from value-based pricing?, “Phar-
macoEconomics” 2011; 29(7): 549–553 [11]; IQWiG, Contra-
cting agencies and funding of iqwig, https://www.iqwig.de/en/
about-us/responsibilities-and-objectives-of-iqwig/contracting-
-agencies-and-funding.2951.html; accessed: 10.04.2015 [23].
Submission of dossier 
by Manufacturer
Assessment 
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Agreement?
Reference price 
applicable?
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SHI/ manufacturer
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no    yes
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reference price system. Knowing that additional benefits 
of particular drugs are low, manufacturers sometimes 
decide not to submit their dossiers at all. Then such prod-
ucts are being directly introduced into the reimbursement 
system, which may turn out to be cheaper for manufac-
turers saving substantial resources necessary for prepara-
tion of full dossiers [6].
Nevertheless, the regular process is associated with 
submission of a dossier to the Federal Joint Committee 
(FJC), being the highest decision making body of the 
joint self-government of physicians, dentists, hospitals 
and health insurance funds in Germany1. The additional 
benefits of a medicine need to be verified either by the 
FJC itself or this task can be transferred to the Institute 
of Quality and Efficiency (IQWiG) [22]. The IQWiG is 
an independent scientific HTA agency, financed through 
levies for inpatient and outpatient medical treatment paid 
by the sickness funds. In other words, the IQWiG is fi-
nanced through contributions from members of all statu-
tory health insurance funds, which are being fixed every 
year by the FJC. The IQWiG assists the FJC in decision 
making and it is divided into eight departments. One of 
them is responsible for producing reports from assess-
ments of pharmaceuticals [9, 10].
Based on the assessment, after an additional hearing 
of manufacturer, the FJC finally decides on the additional 
benefit which a particular medicine could bring. If the de-
cision is negative and no additional benefit is identified, 
a drug is being added to one of already existing reference 
groups. It is assumed in such case that a drug has the 
same effect as other drugs belonging to this group have. 
If a drug cannot be added to the existing reference price 
group, a price of that drug will be similar to its compara-
tor’s price [22, 23].
If additional benefit of a new drug exists, price ne-
gotiations between the SHI and manufacturer take place. 
The process ends with agreement of both parties. If there 
is no agreement, then the arbitration board makes a final 
decision on reimbursement price. Objection of this reim-
bursement price leads to a new evaluation performed by 
the IQWiG [22].
The positive decision on reimbursement of a medi-
cine in Poland is always accompanied with setting its 
price. The HTA and reimbursement processes in Poland 
have been presented in Figure 4. The procedure starts 
with submission of a dossier to the MoH. In case of a new 
molecule or a new indication for use, a copy of a dossier 
is transferred further to the President of the Agency for 
Health Technology Assessment and Tariff System (AOT-
MiT). It is accompanied with a request to prepare a set 
of documentation enabling the MoH to make reimburse-
ment decision. The AOTMiT is publicly financed and it 
is under supervision of the MoH [8].
The set of documentation consists of a verifying anal-
ysis of the AOTMiT, a position paper of the AOTMiT’s 
Transparency Council and a recommendation of the AOT-
MiT’s President. These documents are prepared on a basis 
of HTA report prepared by a pharmaceutical company. 
Neither recommendation of the AOTMiT’s President nor 
appraisal contained in a position paper of the AOTMiT’s 
Submission of dossier 
by Manufacturer
MoH
97 records screened 
for relevance
Assignment of as-
sessment by AOTMiT 
(in case of new 
substances or use 
indications)
Preparation of:
verifying analysis of 
AOTMiT,
position paper of 
Transparency Council 
at AOTMiT,
recommendation of 
AOTMiT President
Price negotiations 
between manufacturer 
and MoH
Reimburesement 
decision of MoH
Figure 4. HTA process in Poland [24].
Source: Own elaboration.
Transparency Council are binding for the MoH in making 
a final decision on reimbursement [24]. Another docu-
ment which is necessary for the MoH to make that deci-
sion is a resolution of the Economic Commission of the 
MoH. This resolution is being issued after price negotia-
tions performed between the Economic Commission and 
a given pharmaceutical company. The differences within 
reimbursement processes between Germany and Poland 
can be highlighted at this point. Whereas in Poland a list 
price of reimbursed medicine is set as a result of negotia-
tions and a reference price is set by the MoH based on 
rules specified in the reimbursement law, in Germany 
a list price is regulated by the market and a reimbursement 
price is negotiated. If a given pharmaceutical’s market 
price is more than 30% cheaper than a negotiated refer-
ence price, a German patient does not have to make a 10% 
co-payment (between EUR 5.00 and EUR 10.00), which 
has been described above [25].
There are also differences between HTA processes in 
Germany and Poland. One of them relates to perspective 
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which should be adopted in economic analyses within 
HTA reports. In Germany the law says that this should 
be a perspective of the insured persons, which means that 
not only the payments of the sickness funds have to be 
taken into account but also the patients’ co-payments. It is 
not clear if also other private expenditures should be con-
sidered in the decision-making. In reality, the perspective 
the IQWiG changes from case to case and sometimes also 
the indirect costs are being considered [10]. In Poland the 
perspective of the entity financing health care services 
(public payer) has to be adopted obligatorily but also the 
social perspective can be included in justified cases [26].
Another difference between both countries can be 
observed within approach to cost-effectiveness thresh-
olds. The IQWiG in Germany uses the efficiency frontier 
approach to make recommendation. In this approach the 
existing therapies provide a threshold for comparison of 
therapeutic benefits and costs between already existing 
therapies and a new medicine. A new drug which pro-
vides benefit equal to that of existing therapies should not 
be more expensive than these therapies [27]. Therefore 
while adopting this approach a flexible threshold is being 
used [10]. Similarly in Poland a medicine, which is not 
more effective than an already reimbursed therapy, can-
not cost more than that therapy. However for new medi-
cines with an added therapeutic value a cost-effectiveness 
threshold is being applied. It is calculated as 3 times GDP 
per capita per one QALY (Quality Adjusted Life Year) or 
LYG (Life Year Gained) obtained due to application of 
a new therapy instead of its old alternative [8].
There are also other differences between the two na-
tional HTA agencies within recommended methodologies 
of performing economic analyses. In Germany the cost-
effectiveness analysis is used [9]. In Poland all kinds of 
economic analyses can be applied in appropriate instances, 
including cost-effectiveness or cost-utility approaches. If 
there is no difference between health effects also the cost 
minimization analysis can be applied [26]. The Polish 
HTA guidelines seem to offer more options, whereas the 
German way of evaluation seems to be more fixed.
Transparency of decision making within drug pricing  
and reimbursement in Germany and Poland
Transparency of decision making within pharmaceu-
tical pricing and reimbursement is crucial for preventing 
corruption and implementing efficient national health 
policy. The transparency entails several issues. For ex-
ample, according to the International Monetary Fund 
it relates to creating “an environment in which the ob-
jectives of policy, its legal, institutional, and economic 
framework, policy decisions and their rationale, data and 
information related to monetary and financial policies, 
and the terms of agenciesʼ accountability, are provided 
to the public in a comprehensible, accessible, and timely 
mannerˮ [28]. On the EU level the Transparency Direc-
tive 89/105/EEC has been issued in order to ensure trans-
parency within control of prices and reimbursement of 
medicinal products [29]. Several requirements for phar-
maceutical reimbursement in the Member States of the 
EU have been set there, including that respective deci-
sions must be made within a specific timeframe; must be 
communicated to the applicant and contain a statement of 
reasons based on objective and verifiable criteria; must 
be open to judicial appeal at national level [29]. These 
requirements are fulfilled both in Germany and Poland.
In Germany the assessments and dossiers, as well as 
results of clinical trials included into HTA must be pub-
lished on the FJC’s webpage (https://www.g-ba.de/infor-
mationen/nutzenbewertung) [6, 11]. In Poland the scope 
of published documentation on processes of medicines 
pricing and reimbursement is smaller. The HTA docu-
mentation is being published on the AOTMiT website 
(www.aotm.gov.pl), including recommendation, HTA 
dossier submitted by applicant and assessment reports 
with comments which can be submitted within seven 
days after publication of these assessments. However the 
published documents have been censored in Poland on 
demand of the pharmaceutical industry, especially exten-
sively until the middle of 2014.
In assessment performed by Jebrail et al. who applied 
33 parameters, the transparency of the IQWiG perfor-
mance was positioned on level of 97% [17]. Analyzing 
application of HTA and pharmacoeconomics into health 
policies of 14 European countries and evaluating nine 
characteristics relevant for decision making processes, 
Marusakova et al. ranked Germany on the second place, 
whereas Poland on the third [18].
Stakeholder involvement in pharmaceutical pricing  
and reimbursement processes in Germany and Poland
There are payers, health care professionals, patients, 
the general public, politicians and producers among 
stakeholders within the pharmaceutical reimbursement 
process. In Germany payers are represented by the SHI, 
which directly performs price negotiations with pharma-
ceutical manufacturers and is involved in valuation of the 
additional benefit of medicines. In addition, five payer 
representatives are part of the FJC [7]. In Poland the 
public payer has its representatives within the Economic 
Commission of the MoH, which is involved in price ne-
gotiations. The Polish public payer has representatives 
also within the Transparency Council of the AOTMiT.
The involvement of health care professionals and pro-
viders seems to be similar in both countries. In Germany, 
similarly to payers also providers are represented in the 
FJC by five members with a voting right [7]. Besides, 
they have also the same rights to make comments as 
everyone else. Providers have no special role in the Pol-
ish process, thus their involvement in both countries is 
rather small. Members of advisory bodies active at vari-
ous stages of decision making processes in Poland should 
have appropriate professional background, experience 
and expertise.
The involvement of representatives of patient or-
ganizations seems to be smaller than that of providers or 
health care professionals. In Germany up to five patient 
representatives can take part in meetings held by the FJC, 
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however without a voting right. Their input is limited to 
contribution to discussions and proposition of agenda 
items. These patient representatives are nominated by the 
national umbrella organizations of self-help groups and 
organizations of consumers or patients [7].
In Germany and Poland the public opinion’s involve-
ment is associated with possibility to provide comments 
on published documents. In addition, the German IQWiG 
has to provide a proposal for the assessment after speci-
fying the research question. Furthermore, the IQWIG 
has to publish an interim report describing the process 
of assessment [10]. The general public has an opportu-
nity to make comments on all of these published docu-
ments. The FJC has no process to elicit the public’s value 
judgement [7]. Therefore initiative and motivation to 
make comments has to originate from inside the gen-
eral public. These comments do not necessarily have to 
change anything about the official decision. Nevertheless 
opportunities for the general public to express their com-
ments on documents before final decision is made are 
bigger in Germany than in Poland.
In Poland politicians are directly involved in the de-
scribed processes, since it is the MoH who makes deci-
sion on drug reimbursement. In Germany politicians are 
not involved in the process.
Obviously, pharmaceutical industry is involved in 
pricing, reimbursement and HTA processes in Poland as 
well as in Germany. In both countries the pharmaceutical 
companies prepare and submit their dossiers starting the 
whole process and then they take part in list price nego-
tiations. However, in Poland the pharmaceutical industry 
can censor documents before making them open to the 
general public, while in Germany it is not possible.
It seems that various stakeholders’ involvement in 
pharmaceutical reimbursement and HTA processes is 
generally higher in Germany than in Poland. Apparently 
the only stakeholder in Poland which is more involved 
in these processes is the MoH. In fact, the German MoH 
is not involved at all, whereas the Polish MoH actually 
makes the decision on medicine’s reimbursement and its 
reference group allocation (reference price is based on 
formal calculations described in the statutory law) and 
the Economic Commission of the MoH negotiates medi-
cines prices.
Discussion
Marusakova et al. evaluated transparency of decision 
making processes in 14 European countries using nine 
criteria, including: “legislative background, implementa-
tion, binding force, institutionalization, qualified personal 
resources availability, existing methodology/guidelines, 
clarity of the process, patient involvement in the process, 
and respecting the deadline of 180 days for issuing a de-
cision” [18]. A ranking of process transparency was then 
prepared, in which the UK system was assessed as the 
most transparent. Germany and Austria were on the sec-
ond place, while Poland and Hungary ranked third [18]. 
This correlates with our findings, suggesting that the Ger-
man processes may be more transparent than Polish. 
Overall involvement of stakeholders is stronger in 
Germany than in Poland, which goes in parallel with 
transparency of the German processes. However, another 
published study based on analysis of benefit assessments 
in Germany showed that although patient preferences were 
included in 26% of analyzed reports, they were practically 
not considered within benefit assessments [19]. This shows 
that utilization of stakeholders involvement in Germany 
still needs to be enhanced. On the other hand, involvement 
and inclusion of more stakeholders could lead to higher 
complexity of processes, making them more difficult to 
understand and lowering their transparency.
In addition, analysis techniques used in the German 
process are very complicated. For lay people it is diffi-
cult to understand the efficiency frontier approach and to 
retrace a decision. It could seem that the fixed threshold 
approach applied in Poland is quite straightforward, so in 
these aspects the Polish system could be more transparent 
than German. However, Jebrail et al. developed an in-
strument to measure transparency of HTA organisations, 
assessing 33 transparency parameters in eight coun-
tries. According to them the IQWiG achieved the best 
result (97% of the maximum score), whereas the Agenzia 
Italiana del Farmaco in Italy scored only 25% [17].
Not only assurance of appropriate level of understand-
ing of pricing and reimbursement, and HTA processes to 
the wider audience is important. If not all information 
on main aspects of these processes is being published, 
the level of their transparency becomes diminished. Ap-
parently the processes in Germany are more transparent 
than in Poland, where even the final HTA recommenda-
tion can be censored and not published in full.
It has to be acknowledged that only scientific reports 
published in German and English languages were taken 
into consideration in this study, which could influence 
findings presented therein.
Conclusions
It can be concluded that both Germany and Poland 
have developed complex processes of pharmaceutical 
pricing and reimbursement, as well as incorporated HTA 
into decision making procedures. The German reimburse-
ment and HTA processes seem to be more transparent 
than Polish. One of the main reasons for that is censoring 
HTA documents before their publication in Poland, still 
occurring although less intensive now than in the pre-
vious years. In addition, involvement of stakeholders in 
Germany seems to be higher than in Poland.
The biggest disadvantage of the German system is its 
high complexity. Using the efficiency frontier approach 
makes the HTA reports difficult for patients to under-
stand. Therefore these reports, although published and 
uncensored, are rarely read by a wide public in Germany.
Note
1 In the German health care system the government del-
egates competencies to membership-based, self-regulated or-
ganizations of payers and providers [1].
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